Agenda Clinical Hematology & Oncology 2025

5-7 p.m.                             

Welcome Dinner

Join us in the Regency Foyer for early registration and a complimentary welcome dinner. This informal, buffet-style dinner will span over a 2-hour period as guests arrive to the hotel.

7 a.m.                 

Registration, Breakfast & View Exhibits

7 a.m.

Breakfast Symposium

Non-CME Activity Hosted by Pfizer

Getting Started and Transitioning to Outpatient Care for Patients with Relapsed or Refractory Multiple Myeloma

Mojtaba Akhtari, MD (Loma Linda University)

7:55 a.m.                           

Welcome & Educational Overview

8 a.m.                 

Peri-operative Thrombocytopenia          

Ted Warkentin, MD

8:30 a.m.                           

Hormonal Therapy and Thrombosis Risk              

Damon Houghton, MD

9 a.m.                 

Barely Abnormal CBCs  

Alice Ma, MD    

9:30 a.m.                           

Panel Discussion/Q&A  

10 a.m.               

Break & View Exhibits

10:15 a.m.         

Antiphospholipid Syndrome: 2024 Update         

Stephan Moll, MD

10:45 a.m.         

Hypereosinophilic Syndrome     

Jason Gotlib, MD

11:15 a.m.         

Investigating Bleeding of an Obscure Cause        

Menaka Pai, MD

11:45 a.m.         

Panel Discussion/Q&A

Noon           

Lunch

Noon

Lunch Symposium A

Non-CME Activity Hosted by Agios

Rethink Thalassemia: A Deep Dive Into Its Pathophysiology, Risks, and Complications (PDF, 110 KB)

Sherif Badawy, MD, MS, MBA (Lurie Children's Hospital)

Lunch Symposium B

Non-CME Activity Hosted by AstraZeneca

A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i (PDF, 2.4 MB)

Sarah Lavasani, MD, MSc, FRCPC (UC Irvine)

1 p.m.                 

What’s New in AML       

Monzr Al Malki, MD

1:30 p.m.                           

Should Patients Still Undergo BMT for Myeloma?

Morie Gertz, MD

2 p.m.                 

Evolving Therapeutic Approaches in Patients with Low-risk MDS             

Aref Al-Kali, MD 

2:30 p.m.                           

Panel Discussion/Q&A

2:45 p.m.                           

Break & View Exhibits

3:15 p.m.                           

Clinical Updates in B-ALL

Wendy Stock, MD

3:45 p.m.                           

Refractory Diffuse Large Cell Lymphoma             

Stephen Schuster, MD

4:15 p.m.                           

HLH and HLH-like Inflammatory Syndromes       

TBD

4:45 p.m.          

Panel Discussion/Q&A

CONCURRENT BREAKOUT SESSIONS

5:15 p.m.          

Breakout #1: Interesting Cases in Thrombosis - Stephan Moll, MD 

Breakout #2: Interesting Cases in Thrombocytopenia - Ted Warkentin, MD 

Breakout #3: Interesting Cases in Bleeding - Alice Ma, MD

Breakout #4: Interesting Cases in Plasma Cell Dyscrasias - Morie Gertz, MD 

6:15 p.m.

Adjourn

7 a.m.                 

Breakfast & View Exhibits

7 a.m.

Breakfast Symposium A

Non-CME Activity Hosted by Pfizer

Treatment Considerations for Specific Populations With HR+/HER2- mBC

Linnea Chap, MD (Beverly Hills Cancer Center)

Breakfast Symposium B

Non-CME Activity Hosted by GSK

Myelofibrosis: Challenges with Disease Management and Considerations for Patient Support (PDF, 1.8 MB)

Julie Huynh-Lu, MS, PA-C (MD Anderson Cancer Center)

Sarah Chittenden, RN, MSN, FNP (GSK)

7:55 a.m.                           

Welcome & Announcements

8 a.m.                 

Ultra Low Her2 Breast Cancer: Pushing the Boundary in IHC 0 and Treatment Implications              

Rena Callahan, MD  

8:30 a.m.                           

Changing Landscape of Sequencing in HR Positive, Her2 Negative Metastatic Breast Cancer              

Aditya Bardia, MD

9 a.m.                 

Sequencing Therapies in Early Triple Negative Breast Cancer      

Laura Huppert, MD

9:30 a.m.                           

Panel Discussion/Q&A

10 a.m.               

Break & View Exhibits

10:30 a.m.         

Neoadjuvant and Adjuvant Therapy for Melanoma         

Gregory Daniels, MD

11 a.m.               

Management of Variant Histology Renal Cell Carcinoma

Sumanta Kumar Pal, MD

11:30 a.m.         

Targeted Therapies in Central Nervous System Metastasis

Seema Nagpal, MD

Noon                   

Panel Discussion/Q&A

12:30 p.m.         

Lunch

12:30 p.m.

Lunch Symposium

Non-CME Activity Hosted by Lilly

Explore the Current Data That Could Help You Recognize/assess Candidates for a CDK4 & 6 Inhibitor

Kelly McCann, MD, PhD (UCLA)

1:30 p.m.                           

Rectal Cancer – Making Sense of TNT, ctDNA, and Surgery: A Case-based, Multidisciplinary Discussion          

Michael Overman, MD – Medical Oncology

Brian Bednarski, MD – Rectal Surgery

Eugene Koay, MD – Radiation Oncology

3:30 p.m.            

Panel Discussion/Q&A  

3:30 p.m.                           

Break & View Exhibits

4 p.m.                

New Targeted Therapies for Gastroesophageal Cancer

J. Randolph Hecht, MD

4:30 p.m. 

Updates in Neuroendocrine Tumors                          

Jonathan Strosberg, MD

5 p.m.               

Panel Discussion/Q&A

5:30 p.m.                           

Adjourn

5:45 p.m.

Dinner Symposium

Non-CME Activity Hosted by Pfizer

7 a.m.                 

Breakfast & View Exhibits

7:55 a.m.                           

Welcome & Announcements

8 a.m.                 

Role of Immune Therapy in Advanced Endometrial Cancer         

Ramez Eskander, MD

8:30 a.m.                           

Updates in the Treatment of Metastatic Soft Tissue Sarcoma     

Mark Agulnik, MD

9 a.m.                 

Genomic Risk Stratification and High Sensitivity Imaging in Localized Prostate Cancer    

Tanya Barauskas Dorff, MD

9:30 a.m.                           

Panel Discussion/Q&A

10 a.m.               

Break & View Exhibits

10:30 a.m.         

Optimal Management of ALK Rearranged NSCLC             

Kamya Sankar, MD 

11 a.m.               

Evidence-Based Management of Hormone Deprivation Symptoms After Cancer

Jennifer Litton, MD

11:30 a.m.         

Prevention, Monitoring, and Long-Term Follow-Up of Cardiovascular Complications in Cancer Survivors

Eric Yang, MD             

Noon                   

Panel Discussion/Q&A

12:30 p.m.         

Final Adjournment

Please note: All times are listed in Pacific Time (PT). Topics, times and speakers are subject to change.